- Home
- HOWL vs ANL Comparison
HOWL vs ANL Comparison
Compare HOWL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- ANL
- Stock Information
- Founded
- HOWL 2017
- ANL 2004
- Country
- HOWL United States
- ANL Cayman Islands
- Employees
- HOWL N/A
- ANL N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- HOWL Health Care
- ANL
- Exchange
- HOWL Nasdaq
- ANL Nasdaq
- Market Cap
- HOWL 64.5M
- ANL 61.8M
- IPO Year
- HOWL 2021
- ANL 2023
- Fundamental
- Price
- HOWL $0.93
- ANL $1.45
- Analyst Decision
- HOWL Strong Buy
- ANL Hold
- Analyst Count
- HOWL 5
- ANL 1
- Target Price
- HOWL $7.00
- ANL N/A
- AVG Volume (30 Days)
- HOWL 732.3K
- ANL 11.3K
- Earning Date
- HOWL 11-04-2025
- ANL 11-07-2025
- Dividend Yield
- HOWL N/A
- ANL N/A
- EPS Growth
- HOWL N/A
- ANL N/A
- EPS
- HOWL N/A
- ANL N/A
- Revenue
- HOWL N/A
- ANL N/A
- Revenue This Year
- HOWL N/A
- ANL N/A
- Revenue Next Year
- HOWL N/A
- ANL N/A
- P/E Ratio
- HOWL N/A
- ANL N/A
- Revenue Growth
- HOWL N/A
- ANL N/A
- 52 Week Low
- HOWL $0.60
- ANL $1.10
- 52 Week High
- HOWL $2.38
- ANL $3.38
- Technical
- Relative Strength Index (RSI)
- HOWL 24.51
- ANL 39.83
- Support Level
- HOWL $0.89
- ANL $1.41
- Resistance Level
- HOWL $1.00
- ANL $1.60
- Average True Range (ATR)
- HOWL 0.11
- ANL 0.13
- MACD
- HOWL -0.03
- ANL 0.01
- Stochastic Oscillator
- HOWL 5.58
- ANL 39.44
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.